Phaseline

Companies › Longbio Pharma

Longbio Pharma: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 2 Phase 2, 2 Phase 1, 1 Phase 3; Immunology, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LP-003–Phase 3Seasonal Allergic Rhinitis; Allergic Asthma; Allergic Diseases; Chronic Spontaneous UrticariaNov 2026
LP-005 Injection
Complement pathway inhibitor
–Phase 2PNH - Paroxysmal Nocturnal HemoglobinuriaMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07148557LP-003Phase 1Allergic DiseasesImmunologyMay 2026
NCT06604949LP-003Phase 1Chronic Spontaneous UrticariaImmunologyNov 2026
NCT07291284LP-003Phase 3Seasonal Allergic RhinitisImmunologyDec 2026
NCT07342803LP-003Phase 2Allergic AsthmaImmunologyDec 2027
NCT07212426LP-005 InjectionPhase 2PNH - Paroxysmal Nocturnal HemoglobinuriaHematologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Octapharma Kedrion Paradigm Biopharmaceuticals Arthrosi Therapeutics Disc Medicine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.